Revenue $m, page-23

Infusion business appears to be the only profitable part of AHZ ATM - nuts and bolts part of business - really just an Australian based agency for the hardware and consumables.
ADAPT stuff has potential but slowly getting market share - surgeons don't change their ways in a hurry- all new products will need time in market for acceptance
Immunotherapy division - was the blue sky imho - but recent vaccine results not great and a fair bit of cash been thrown this way

A definite US bias developing - directors, reporting etc .

PERHAPS grand plan is :
Sell infusion business - simple - probably to Australian based business in same field. Easily quantifiable
Give way immunotherapy- write off ( unsure if any value obtainable by selling )
Grind away at ADAPT products and eventually get bought out by a bigger player ( US based company in medical devices) but probably when cash strapped. Jobs for the boys included

Result for shareholders- hmmmmmmm !

Any way these are just my ramblings and probably won't happen but gives good for thought